D053663Chemicals & DrugsD12.776.543.750.705.852.420.600.300D23.050.301.264.035.413D23.101.100.110.4134110.988213Interleukin-13 Receptor alpha2 Subunitprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson2.02520.08638624research area of0.6296020.08741678subject area forAnesthesiologyCancer BiologyWake Forest School of MedicineWaldemarDebinskiWaldemar Debinski MD, PhD36.08959100000000-80.26859900000000201Debinski, WaldemarProfessorStevenKridelSteven J. Kridel PhD36.09032400000000-80.26649100000000902Kridel, StevenAssociate ProfessorTieLiuTie F. Liu MD, PhD36.09032400000000-80.26649100000000981Liu, TieInstructor28562337Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz AOncotargetSattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27; 8(26):42997-43007.Oncotarget2017-06-27T00:00:002017IL13RA2 targeted alpha particle therapy against glioblastomas.Surgery, Oncology24147065Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DMPloS oneDebinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One. 2013; 8(10):e77719.PLoS One2013-10-16T00:00:002013New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1InstructorInstructorKiran KumarSolingapuram SaixtKq6p2U9RqiXKrPzBwRYVWrnDMdZvk=Kiran Kumar Solingapuram Sai PhD36.08808900000000-80.268484000000001587Solingapuram Sai, Kiran KumarAssociate ProfessorDiagnostic Radiology18976118Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski WCancer biotherapy & radiopharmaceuticalsMintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm. 2008 Oct; 23(5):581-9.Cancer Biother Radiopharm2008-10-01T00:00:002008Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.21946118Pandya H, Gibo DM, Garg S, Kridel S, Debinski WNeuro-oncologyPandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol. 2012 Jan; 14(1):6-18.Neuro Oncol2011-09-26T00:00:002011An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts.22952195Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz ANeuro-oncologyNguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct; 14(10):1239-53.Neuro Oncol2012-09-05T00:00:002012A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker.